Mapi Pharma Announces Virtual Key Opinion Leader Event on Innovative MS Therapy

Mapi Pharma Ltd., a clinical-stage biopharmaceutical company focused on long-acting depot injectable treatments, announced today that it will host a virtual Key Opinion Leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET to discuss its once-a-month Glatiramer Acetate Depot (GA Depot) treatment for multiple sclerosis. The free online event will bring together leading experts in neurology to explore the unmet needs, treatment landscape and clinical progress of this potential new therapy for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS).

Event Highlights and Expert Presentations

The virtual session will feature presentations by two renowned neurologists:

• Aaron Miller, MD, Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai, who will discuss the unmet clinical needs and evolving treatment landscape for MS.
• Carlo S. Tornatore, MD, Regional Chief of Neurology for MedStar Health and Neurologist-in-Chief at MedStar Georgetown University Hospital, who will share insights from clinical experience and research.

Mapi’s Vice President of Research & Development, Shai Rubnov, PhD, will provide an overview of the company’s depot technologies, product pipeline and regulatory strategy. Ehud Marom, Mapi’s Chairman and CEO, will address financial aspects of the program and answer questions from participants during a live Q&A session following the presentations.

About Glatiramer Acetate Depot

The Glatiramer Acetate Depot (GA Depot) is an investigational intramuscular formulation designed as a once-a-month injectable treatment for people living with multiple sclerosis. The depot formulation leverages long-acting delivery technology that could offer a more convenient dosing schedule compared with traditional options.

GA Depot is currently being studied in both RMS and PPMS patient populations. In Germany, the RMS indication is in a final review process, and a global Phase III trial for PPMS is beginning. Mapi’s leadership team will discuss results from Phase II trials—where GA Depot demonstrated stable disability scores and strong tolerability—and supportive Phase III data for RMS during the March event.

Clinical Progress and Research Findings

In an open-label Phase IIa study of patients with PPMS, GA Depot showed positive clinical outcomes. Most participants maintained stable neurological function over three years of treatment with either 25 mg or 40 mg doses administered monthly. The majority remained free from confirmed disability progression, and many showed stable results on physical performance assessments such as the 9-Hole Peg Test and Timed 25-Foot Walk. Treatment was generally well tolerated, with predominantly mild adverse events.

These results were highlighted at the ACTRIMS Forum 2026 and will be part of the discussion at the upcoming KOL event. Company leaders will also explain registration steps and the commercial outlook for GA Depot across indications.

Registration and Participation Details

Interested participants are required to register in advance to join the live webcast. A replay will be made available for those unable to attend at the scheduled time. During the live session, attendees can submit questions for the panelists to be addressed during the Q&A section.

About Mapi Pharma

Mapi Pharma Ltd. is a biopharmaceutical company headquartered in Ness Ziona, Israel, focused on developing complex active pharmaceutical ingredients and long-acting depot injectable therapies that address unmet medical needs across multiple therapeutic areas. The company’s lead program, GA Depot, is being developed in partnership with Viatris under an exclusive licensing agreement for RMS. Mapi’s broader pipeline includes long-acting injectables for conditions such as diabetes, schizophrenia and other chronic diseases.

With integrated manufacturing capabilities and a robust intellectual property portfolio, Mapi aims to bring innovative, patient-centric therapies to market globally.

#MapiPharma #MultipleSclerosis #GlatiramerAcetateDepot #MSResearch #SlimScan #GrowthStocks #CANSLIM